The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Detection of Isolated Tumor Cells in Bone Marrow Is an Independent Prognostic Factor in Breast Cancer
Abstract
Purpose: This study was performed to disclose the clinical impact of isolated tumor cell (ITC) detection in bone marrow (BM) in breast cancer. Patients and Methods: BM aspirates were collected from 817 patients at primary surgery. Tumor cells in BM were detected by immunocytochemistry using anticytokeratin antibodies (AE1/AE3). Analyses of the primary tumor included histologic grading, vascular invasion, and immunohistochemical detection of c-erbB-2, cathepsin D, p53, and estrogen receptor (ER)/progesterone receptor (PgR) expression. These analyses were compared with clinical outcome. The median follow-up was 49 months. Results: ITC were detected in 13.2% of the patients. The detection rate rose with increasing tumor size (P = .011) and lymph node involvement (P < .001). Systemic relapse and death from breast cancer occurred in 31.7% and 26.9% of the BM-positive patients versus 13.7% and 10.9% of BM-negative patients, respectively (P < .001). Analyzing node-positive and node-negative patients separately, ITC positivity was associated with poor prognosis in the node-positive group and in node-negative patients not receiving adjuvant therapy (T1N0). In multivariate analysis, ITC in BM was an independent prognostic factor together with node, tumor, and ER/PgR status, histologic grade, and vascular invasion. In separate analysis of the T1N0 patients, histologic grade was independently associated with both distant disease-free survival (DDFS) and breast cancer–specific survival (BCSS), ITC detection was associated with BCSS, and vascular invasion was associated with DDFS. Conclusion: ITC in BM is an independent predictor of DDFS and BCSS. An unfavorable prognosis was observed for node-positive patients and for node-negative patients not receiving systemic therapy. A combination of several independent prognostic factors can classify subgroups of patients into excellent and high-risk prognosis groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Braun, S., Pantel, K., Müller, P., Janni, W., Hepp, F., Kentenich, C. R. M., Gastroph, S., Wischnik, A., Dimpfl, T., Kindermann, G., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002243420801 · Cited by 923
Pantel, K., Schlimok, G., Braun, S., Kutter, D., Lindemann, F., Schaller, G., Funke, I., Izbicki, J. R., & Riethmuller, G. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.17.1419 · Cited by 503
Detection and Clinical Importance of Micrometastatic Disease
Pantel, K., Cote, R. J., & Fodstad, O. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.13.1113 · Cited by 493
Cited by
Breast cancer metastasis: markers and models
Weigelt, B., Peterse, J. L., & van't Veer, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1670 · Cited by 2,232
A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., Schlimok, G., Diel, I. J., Gerber, B., Gebauer, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050434 · Cited by 1,379
Self-citationDissecting the metastatic cascade
Pantel, K., & Brakenhoff, R. H. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1370 · Cited by 1,281
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Pantel, K., Alix-Panabières, C., & Riethdorf, S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.44 · Cited by 643
Sørlie, T., Wang, Y., Xiao, C., Johnsen, H., Naume, B., Samaha, R. R., & Børresen-Dale, A.-L. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-127 · Cited by 387
Self-citationPierga, J.-Y., Bidard, F.-C., Mathiot, C., Brain, E., Delaloge, S., Giachetti, S., de Cremoux, P., Salmon, R., Vincent-Salomon, A., & Marty, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0030 · Cited by 369
Novel patterns of genome rearrangement and their association with survival in breast cancer
Hicks, J., Krasnitz, A., Lakshmi, B., Navin, N. E., Riggs, M., Leibu, E., Esposito, D., Alexander, J., Troge, J., Grubor, V., et al. (2006) · Genome Research · doi:10.1101/gr.5460106 · Cited by 319
Self-citationReview: Biological relevance of disseminated tumor cells in cancer patients
Riethdorf, S., Wikman, H., & Pantel, K. (2008) · International Journal of Cancer · doi:10.1002/ijc.23825 · Cited by 309
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation
Nilsen, G., Liestøl, K., Van Loo, P., Moen Vollan, H. K., Eide, M. B., Rueda, O. M., Chin, S.-F., Russell, R., Baumbusch, L. O., Caldas, C., et al. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-591 · Cited by 303
Significance, detection and markers of disseminated breast cancer cells
Lacroix, M. (2006) · Endocrine-Related Cancer · doi:10.1677/erc-06-0001 · Cited by 293
Xenidis, N., Perraki, M., Kafousi, M., Apostolaki, S., Bolonaki, I., Stathopoulou, A., Kalbakis, K., Androulakis, N., Kouroussis, C., Pallis, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5948 · Cited by 263
Schardt, J. A., Meyer, M., Hartmann, C. H., Schubert, F., Schmidt-Kittler, O., Fuhrmann, C., Polzer, B., Petronio, M., Eils, R., & Klein, C. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.003 · Cited by 259
Wülfing, P., Borchard, J., Buerger, H., Heidl, S., Zänker, K. S., Kiesel, L., & Brandt, B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2087 · Cited by 258
Metadata
- Authors
- Wiedswang, G., Borgen, E., Kåresen, R., Kvalheim, G., Nesland, J. M., Qvist, H., Schlichting, E., Sauer, T., Janbu, J., Harbitz, T., & Naume, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-09-15
- Volume
- 21
- Issue
- 18
- Pages
- 3469-3478
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2119480061
- Cited by
- 284
- References
- 23
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.